Report 02: Pfizer – 136 Deaths and 1625 Serious Cases of ‘Ineffectiveness’ Revealed

In early December 2020 Pfizer became aware that their vaccine may have only limited efficacy.
And for three more months, they received multiple reports of vaccine failure and ineffectiveness.
They would only admit this in Spring 2021.

PFIZER’S 5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENTS REPORTS ON VACCINE EFFICACY AND NEW REPORTS/STUDIES RAISE CONCERNS OF VACCINE INEFFECTIVENESS, FAILURE, AND LIMITED DURABILITY.

Astonishingly, Pfizer’s internal documents that were recently released by court order revealed  that beginning on December 1, 2020,

Pfizer was aware that the vaccine that was pushed upon the American people had limited efficacy.

For the next 3 months, from 12/1/2020-2/28/2021, Pfizer’s 5.3.6 cumulative analysis of post authorization adverse events reports indicate that Pfizer received multiple reports of both vaccine failure and vaccine ineffectiveness.

According to Pfizer’s cumulative analysis, there were 16 serious cases of vaccine failure and 1,625 serious cases of vaccine ineffectiveness reported. (Page 14).

In the same Pfizer document,  Covid-19 is identified as an adverse event special interest (AESI), with 3,067 cases of Covid-19 reported after receiving the vaccine. From that number, there were 2,585 serious relevant events, including Covid-19 pneumonia, and 136 people died. (Page 17)

Pfizer excluded cases from analysis, including 546 cases in which SARS-CoV-2 infection was developed  between days 1-13 from the first dose. (Page 15).  After allowing for Pfizer’s exclusion of some cases, this data still reveals multiple serious cases, including fatalities, indicating there is vaccine failure and vaccine ineffectiveness with Pfizer’s vaccine.  And worse, Pfizer, who is responsible for the post authorization analysis, admits that there are limitations in the reporting and that “the magnitude of underreporting is unknown.” (Page 5).

Even though there were multiple reports of lack of vaccine efficacy, Pfizer stated in the confidential document that “No new safety signals of vaccine lack of efficacy have emerged based on a review of these cases.” (Page 15)

However, just as Dr. Fauci anticipated in 2020, the duration of vaccine protection is limited.

Dr. Fauci stated that “If Covid-19 acts like other coronaviruses, it likely isn’t going to be a long duration of immunity,” (https://www.cnbc.com/2020/06/02/dr-anthony-fauci-says-theres-a-chance-coronavirus-vaccine-may-not-provide-immunity-for-very-long.html

Dr. Fauci told Dr. Collins in 2020 regarding the Covid-19 vaccines that “We’re going to assume that there’s a degree of protection, but we have to assume that it’s going to be finite. It’s not going to be like a measles vaccine. So there’s going to be follow-up in those cases to see if we need a boost. We may need a boost to continue the protection.”

Excerpts from NIH Director Dr. Collins’s conversation with NIAID Director Dr. Fauci

https://newsinhealth.nih.gov/2020/08/dr-anthony-fauci-covid-19-vaccines

The findings from a Swedish study from 12/28/2020 to 10/4/2021 show that there was, “… a progressive waning of vaccine effectiveness of BNT162b2 (Pfizer) against SARS-CoV-2 infection of any severity, with no vaccine effectiveness detected from 7 months onwards.”

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00089-7/fulltext

The study found that “Unlike natural immunity, which appears robust with little waning for a year following infection,

there is a gradual but relatively rapid waning in vaccine immunity against infection following the second dose.” [emphasis added]

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00277-X/fulltext?rss%3Dyes

“Waning immunity (is) also known as secondary vaccine failure.” Israel attributed an increase in infections and hospitalizations of vaccinated persons due to a “combination of waning vaccine immunity… and from potentially reduced effectiveness of the (Pfizer) vaccine against the delta variant.”

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02249-2/fulltext

A report from the FDA indicates that the efficacy of Pfizer’s vaccine wanes.

• Immunogenicity (measures how well a vaccine is working) of the original strain of SARS-CoV2, was identified in a study as follows:
• Neutralizing antibody titers against original strain: 762 1 month post 2nd dose.
• Neutralizing antibody titers decreased to 136 prior to first booster.
• The antibody titers increased to 2374.2 1 month post booster

https://www.fda.gov/media/152239/download

Now there are reports that the efficacy of the booster is waning after 3-6 months.

“Emerging evidence, including data from Kaiser Permanente Southern California (KPSC), suggests that effectiveness against both symptomatic COVID-19  and severe disease caused by Omicron wanes 3 to 6 months after receipt of an initial booster (third dose). Thus, additional booster doses may be needed to ensure individuals remain adequately protected.” https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-us-emergency-use-authorization

On March 15, 2022,  Pfizer submitted an application for EUA of an additional booster dose for older adults who have received an initial booster. On March 29, 2022, the FDA authorized a

second Pfizer Covid-19 vaccine booster in persons aged 50 years and older in addition to immunocompromised persons aged 12 years and older.

In support of yet another booster, Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, stated that “current evidence suggests some waning of protection over time against serious outcomes from Covid-19….and a second booster dose…. could help increase protection levels for …higher-risk individuals.” [emphasis added] https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-second-booster-dose-two-covid-19-vaccines-older-and

There is an abundance of evidence that the Pfizer vaccine has a serious durability problem, resulting in waning protection and vaccine failure.

In a risk/benefit analysis, the risk of known serious adverse events, including death, from the vaccine outweighs the possible benefit of a vaccine that we know will fail.

The vaccine program must stop. We need to focus on early treatment and natural immunity.

Vicki Goldstein, RN, JD